Biotech stocks are regaining some lost momentum after Wednesday's Trump-inspired selloff that took a toll on the sentiment on pharma sector.
The weakness was so stark that it made CNBC's Brian Sullivan tweet that biotechs/healthcare was the only sector to have been left out of what seemed to be a market-wide rally on Wednesday.
But, the month of January offers some catalysts for biotech investors to make some money from the sector. There are certain biopharma stocks investors should keep on their radar for the remainder of this month.
Following is a look at several biotech catalysts this month, according to BioPharmCatalyst.
Upcoming Catalysts
The FDA is slated for a response on the NDA of baricitinib, Incyte Corporation INCY’s rheumatoid arthritis drug candidate, by January 19, 2017. Baricitinib was submitted in an NDA in January 2016. The drug is being developed in partnership with Eli Lilly and Co LLY. In December, European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion on baricitinib.FibroGen Inc FGEN will release an abstract of its Phase 2 study of its pancreatic cancer drug, FG-3019, on January 17. The data is due at ASCO GI on January 20.The PDUFA date for Synergy Pharmaceuticals Inc SGYP’ plecanatide for the treatment of chronic idiopathic constipation is January 29.Neurocrine Biosciences, Inc. NBIX is expected to announce Phase 2 data of its Tourette syndrome treatment, INGREZZA, in the week of January 16.Heron Therapeutics Inc HRTX is set to file its NDA for HTX-019 for prevention of chemotherapy-induced nausea and vomiting in January.In January, Tenax Therapeutics Inc TENX is expected to release Phase 3 top-line data for levosimendan, which is being studied for reduction of the incidence of low cardiac output syndrome during cardiac surgery.Dimension Therapeutics Inc DMTX is set to announce Phase 1/2 initial data for hemophilia B treatment, DTX101, this month.At last check, shares of iShares NASDAQ Biotechnology Index (ETF) IBB rose 1.19 percent to $282.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
